www.dailypolitical.com ·
Evaxion a S Nasdaqevax Releases Earnings Results Misses Expectations by 0 43 Eps
Topic context
This topic has been covered 256601 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedEvaxion A/S, a clinical-stage biotech, missed earnings expectations, but the commercial mechanism is weak as the company has no approved product revenue. The primary commercial signal is the EVX-01 trial data and polio vaccine collaboration, which could affect future licensing revenue or partnership terms. No immediate product price or supply chain impact.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Evaxion reported Q1 2026 EPS of ($0.44), missing expectations by ($0.43).
- EVX-01 phase II trial achieved 86% immunogenicity rate.
- Three-year clinical outcome data for EVX-01 expected H2 2026.
- Collaboration with Gates Foundation on novel polio vaccine.
- Cash reserve of $18.4 million projected to last until H2 2027.
EVX-01 (cancer vaccine) and novel polio vaccine may see flat impact in mid-term; modest revaluation expected in 2-4 weeks.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
Related stories
finance.yahoo.com
Eurodry Edry Q1 2026 Earnings
zerohedge.com
Europe Primed Lower Open Amid Lack Progress Usiran Hefty Speaker Slate Nvidia Earnings Due
fool.com
Keysight Keys Q2 2026 Earnings Transcript
marketscreener.com
Dax Remains in Choppy Waters as Earnings Season Winds Down Ce7f5bd3d08cfe2d
fool.com